Welcome to. January 26, The Mayflower Hotel Washington, DC USA
|
|
- Brandon Gray
- 6 years ago
- Views:
Transcription
1 Welcome to January 26, 2015 The Mayflower Hotel Washington, DC USA
2 Mission Statement Provide a venue for biotechnology/biological product discussion that focuses on relevant CMC issues throughout the lifecycle of the product Foster collaborative technical and regulatory interactions Share information with the regulatory agencies to assist them in merging good scientific and regulatory practices
3 CMC Strategy Forum History The CMC Strategy Forum was launched in 2002 from the well established WCBP Symposium. To date, 35 Forums have been held in the US (typically 3 per year) resulting in the publication of 27 white papers on a wide variety of CMC topics. The CMC Forum Europe was launched in 2007 with support from the Biotech Working Party/EMA and quickly became a successful annual event.
4 CMC Strategy Forum History The CMC Forum Japan was launched in 2012 with support from the PMDA and JPMA and has been very successful for the first three years. The inaugural CMC Forum Latin America was launched in August 2014 with support from ANVISA (Brasil), local industry, as well as multiple LatAm regulatory agencies and was very successful. The 2 nd CMC Forum Latin America will be held in August 2015.
5 CMC Strategy Forum Global Steering Committee Siddharth Advant, Kemwell Biopharma, USA John Dougherty, Eli Lilly and Company, USA Junichi Koga, Daiichi Sankyo Co., Ltd., Japan Steven Kozlowski, CDER, FDA, USA Rohin Mhatre, Biogen Idec, USA Anthony Mire-Sluis, Amgen Inc., USA Wassim Nashabeh, F. Hoffmann-La Roche Ltd., Switzerland (Chair) Ilona Reischl, BASG / AGES, Austria Anthony Ridgway, Health Canada, Canada Nadine Ritter, Global Biotech Experts, LLC, USA Mark Schenerman, MedImmune, USA Thomas Schreitmüller, F. Hoffmann-La Roche Ltd., Switzerland Karin Sewerin, BioTech Development AB, Sweden
6 Find out more about past CMC Strategy Forums Look under ARCHIVES for past Forum information and publications.
7 CMC Forum Format The Forum has two components: - Presentations and case studies (frame the discussion) - Workshops where open dialogue and exchange of ideas among participants is highly encouraged Typically each workshop will address about 3 specific questions related to a given topic The workshop success is dependent on active engagement of the participants
8 North America Program Committee Siddharth Advant, Kemwell Biopharma Yves Aubin, Health Canada John Bishop, CBER, FDA Barry Cherney, Amgen Inc. JR Dobbins, Eli Lilly and Company Julia Edwards, Biogen Idec John Hennessey, Novadigm Therapeutics, Inc. Joseph Kutza, MedImmune, A member of the AstraZeneca Group Kimberly May, Merck & Co., Inc. Anthony Mire-Sluis, Amgen Inc.
9 North America Program Committee continued Stefanie Pluschkell, Pfizer, Inc. Nadine Ritter, Global Biotech Experts, LLC Reb Russell, Bristol-Myers Squibb Company Dieter Schmalzing, Genentech, a Member of the Roche Group Timothy Schofield, MedImmune, A member of the AstraZeneca Group Zahra Shahrokh, STC Biologics, Inc. and ZDev Consulting Jeffrey Staecker, Genzyme, a Sanofi company Andrew Weiskopf, Biogen Idec
10 Sustaining Program Partners Diamond Program Partner Genentech, a Member of the Roche Group Platinum Program Partners AbbVie, Inc. Biogen Idec MedImmune, A member of the AstraZeneca Group Silver Program Partner Pfizer, Inc.
11 Forum Program Partners Amgen Inc. Genzyme, a Sanofi company Gilead Sciences Janssen Pharmaceutical R&D, LLC Merck & Co., Inc. National Institute of Standards and Technology (NIST) Novo Nordisk A/S
12 Leading Media Partners BioProcess International International Pharmaceutical Quality Media Partners American Laboratory American Pharmaceutical Review The Analytical Scientist BioProcessing Journal BioTech International Genetic Engineering & Biotechnology News LCGC North America The Medicine Maker / The Pathologist Pharmaceutical Outsourcing RSC Advances separationsnow.com Technology Networks Limited
13 Special Thanks to CASSS Staff: Karen A. Bertani, CMP, Director of Meetings (CMC Forum Manager) Stephanie L. Flores, CAE, Executive Director Anna Lingel, Project Coordinator Linda Mansouria, CMP, CMM, Manager of Meetings & Events Renee Olson, Senior Program Manager Catherine Stewart, Director of Finance Audio-Visual Support: Michael Johnstone MJ Audio-Visual Productions
14 CMC Strategy Forum January 2015 Combination Products for Biopharmaceuticals: Emerging Trends in Development, GMPs and Regulatory Expectations Forum Co-Chairs: Sarah Kennett, CDER, FDA, USA Andrew Weiskopf, Biogen Idec, USA Scientific Organizing Committee: Siddharth Advant, Kemwell Biopharma, USA Jee Chung, CDER, FDA, USA Gary Hartman, Amgen Inc., USA Mark Lee, CBER, FDA, USA Lana Shiu, CDRH, FDA, USA John Towns, Eli Lilly and Company
15 CMC Strategy Forum January 2015 Attendees pre-registered 196 (Combo Products) Attendees pre-registered 161 (Host Cell Proteins) Number of regulators pre-registered 50 (total) Number of companies represented 88 (total) Number of countries represented 15 (Australia, Austria, Brasil, Canada, China, Denmark, France, Germany, Ireland, Japan, Netherlands, Sweden, Switzerland, United Kingdom, USA)
16 CMC Strategy Forum Summer 2012 Such delivery devices fall under the device regulations and have vastly different design, development, and validation requirements than the protein drug product itself the regulatory environment has changed whereby biological drug product, in even simple delivery systems, are now considered combination products
17 A lot can happen in 2 ½ years FDA s pen, jet, related injectors guidance finalized FDA glass syringe guidance to supplement ISO cgmp Requirements for Combination Products become effective More experience gained with Design Controls, Human Factors guidance, etc.
18 A lot can happen in 2 ½ DAYS!
Welcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to the CMC Strategy Forum Prior Knowledge: Learning from Our Successes and Failures to Improve Product Development and Manufacturing
Welcome to the CMC Strategy Forum Prior Knowledge: Learning from Our Successes and Failures to Improve Product Development and Manufacturing We are pleased to welcome you to the CMC Strategy Forum. The
More informationWelcome to the CMC Strategy Forum Phase-appropriate Method Validation Strategies: Policies and Practices to Support Clinical Development
Welcome to the CMC Strategy Forum Phase-appropriate Method Validation Strategies: Policies and Practices to Support Clinical Development We are pleased to welcome you to the CMC Strategy Forum. The purpose
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to the CMC Strategy Forum (July 20-21, 2016)
Welcome to the CMC Strategy Forum (July 20-21, 2016) We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product
More informationWelcome to the CMC Strategy Forum Europe 2017
Welcome to the CMC Strategy Forum Europe 2017 The 11 th annual CMC Strategy Forum Europe, organized by CASSS, will explore a number of critical topics focused on improving the quality in development and
More informationWelcome to the CMC Strategy Forum Europe 2018
Welcome to the CMC Strategy Forum Europe 2018 The 12 th annual CMC Strategy Forum Europe, organized by CASSS, will explore many critical topics focused on improving the quality in development and manufacturing
More informationThe first CMC Strategy Forum
B i op r o c e s s Technical Quality by Design: The Next Phase Potential Regulatory Implications and Filing of QbD Data Anthony Mire-Sluis, Mark Schenerman, Rohin Mhatre, Siddharth Advant, John Dougherty,
More informationWelcome to the CMC Strategy Forum Europe 2014 Improving Biopharmaceutical Product Quality: Moving Implementation Forward
Welcome to the CMC Strategy Forum Europe 2014 Improving Biopharmaceutical Product Quality: Moving Implementation Forward The eighth annual CMC Strategy Forum Europe, organized by CASSS - An International
More information4 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2015)
4 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2015) Symposium Co-chairs: Jamie Moore, Genentech, a Member of the Roche Group Linda Narhi, Amgen Inc. April 13-15, 2015
More informationMultiproduct Facility Design and Control for Biologics
F l e x-faci liti es Design Multiproduct Facility Design and Control for Biologics Challenges and Considerations Bo Chi, Julia Edwards, Jun Park, Stefanie Pluschkell, Nancy Waites, Elizabeth Yamashita,
More informationWelcome to the CMC Strategy Forum Europe 2009: CMC Perspectives on Biological Investigational Medicinal Products in Clinical Trials
Welcome to the CMC Strategy Forum Europe 2009: CMC Perspectives on Biological Investigational Medicinal Products in Clinical Trials The organizers of the CMC Strategy Forum Europe, sponsored by CASSS,
More information14th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2017)
14th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2017) Symposium Co-Chairs: Michael Boyne, BioTechLogic, Inc. Eef Dirksen, Synthon Biopharmaceuticals
More informationThe number of biotherapeutics on
B i op r o c e s s Technical Analysis and Immunogenic Potential of Aggregates and Particles A Practical Approach, Part 1 Anthony Mire-Sluis, Barry Cherney, Russell Madsen, Alla Polozova, Amy Rosenberg,
More informationWCBP th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products
WCBP 2014 18 th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products Symposium Co-Chairs Laura Bass, Pfizer, Inc. Arifa Khan, CBER, FDA Marjorie Shapiro, CDER,
More informationAs defined in the US Code of
Technical B i op r o c e s s The Roles of Bioactivity Assays in Lot Release and Stability Testing by Noel Rieder, Hélène Gazzano-Santoro, Mark Schenerman, Robert Strause, Chana Fuchs, and Anthony Mire-Sluis,
More informationImmunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009
Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009 Committee Leadership Dr. Ellen Evans (Schering-Plough Research Institute), Chair Dr. Tom Kawabata (Pfizer Inc.), Vice
More informationThe State of QbD in the Biopharmaceutical Industry Conference
The State of QbD in the Biopharmaceutical Industry Conference Criticality Assessment, Design Space Implementation and Control 10 11 April 2013 Sheraton Fisherman s Wharf San Francisco, California USA Sponsored
More informationThe 13th WCBP CMC Strategy
FOCUS ON... DIsposableS Extractables and Leachables Challenges and Strategies in Biopharmaceutical Development Anthony Mire-Sluis, Stacey Ma, and Ingrid Markovic, with Lorna McLeod The 13th WCBP CMC Strategy
More informationCMC Strategy Forum Prague Enda Moran EBE Satellite Session, 06 May 2013
CMC Strategy Forum Prague 2013 Enda Moran EBE Satellite Session, 06 May 2013 European Biopharmaceutical Enterprises EBE s VISION: fostering innovation, and promote favorable business and regulatory conditions
More informationPHARMACEUTICAL & BIOTECHNOLOGY QUALITY CONTROL. Early Investment in Characterization Pays Dividends, CMC Forum Participants Agree
F-D-C REPORTS FOUNDED 1939 $625 A YEAR www.thegoldsheet.com The Gold Sheet PHARMACEUTICAL & BIOTECHNOLOGY QUALITY CONTROL THE NEWS THIS ISSUE Vol. 40, No. 6 BIOTECH PRODUCT REFERENCE STANDARDS are drawing
More informationThe 15th WCBP CMC Strategy
B i op r o c e s s Technical Raw Material Control Strategies for Bioprocesses by Gregory Beck, Mark Schenerman, John Dougherty, Ruth Cordoba-Rodriguez, Christopher Joneckis, Anthony Mire-Sluis, and Lorna
More informationParadigm Change in Manufacturing Operations
Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cgmp to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance) Paradigm Change
More informationIndustry View on the Relative Importance of Clonality of Biopharmaceutical-Producing Cell Lines
Industry View on the Relative Importance of Clonality of Biopharmaceutical-Producing Cell Lines Christopher Frye, Eli Lilly & Company, Indianapolis IN Rohini Deshpande, Amgen Inc, Thousand Oaks CA Scott
More informationThe Scientific Organizing Committee gratefully acknowledges the Symposium Program Partners for their generous support of WCBP 2018:
The Scientific Organizing Committee gratefully acknowledges the Symposium Program Partners for their generous support of WCBP 2018: Diamond Program Partners Agilent Technologies Catalent Pharma Services
More information12th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2015)
12th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2015) Symposium Co-Chairs: Steven Cohen, Northeastern University Christopher Yu, Genentech, a
More informationPRELIMINARY PROGRAM WCBP th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products
PRELIMINARY PROGRAM WCBP 2016 20 th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products Symposium Co-Chairs: Michael Kennedy, CBER Juhong Liu, CDER Brian
More informationInnovation for Pharma to engage with the mobile user.
www.healthnetworkcommunications.com/mobile Innovation for Pharma to engage with the mobile user 24-27 April 2012 Sheraton Hotel, Amsterdam, The Netherlands created by sponsor endorsed by Smart phones and
More informationPost-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool
Post-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool Dr. Markus Goese Lead EU CMC Regulatory Policy F. Hoffmann-La Roche Ltd, Basel - Switzerland Presentation
More informationNOVEMBER 13, 2016 Welcome Drinks Reception NOVEMBER 14, 2016 Registration and Breakfast Chair s Welcome Address Patrick Yang Genentech
ren NOVEMBER 13, 2016 6:00 pm - 7:00 pm Welcome Drinks Reception NOVEMBER 14, 2016 7:15 am - 8:15 am Registration and Breakfast 8:15 am - 8:30 am Chair s Welcome Address Patrick Yang Former EVP, Technical
More informationCurrent Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V
Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V Abstract: Indian pharmaceutical industry has proved manufacture of global quality pharmaceutical products
More informationCMO. Quality Oversight & Risk Management. 4 th. Maintaining Quality and Compliance With CMOs in a Changing Regulatory Environment
4 th CMO Quality Oversight & Risk Management Maintaining Quality and Compliance With CMOs in a Changing Regulatory Environment April 23-24, 2014 Hyatt Regency Boston Boston, MA New for 2014: n REGULATORY
More informationAn Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America
An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America SPEAKERS: Janett Mugaburu-Richards, M.S. Pfizer Inc. Kavita Ramalingam Iyer, Ph.D Merck & Co., Inc. Contents
More informationConnecting People, Science and Regulation
Connecting People, Science and Regulation Bethesda Towers 4350 East West Highway, Ste 600 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org PDA Europe ggmbh Am Borsigturm
More informationAn Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen
An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies SPEAKER: Suzanne Murray Biogen Contents 1. BioPhorum Operations Group (BPOG) and the Post-approvals
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationAnalytical Technologies Europe: Symposium on the Practical Applications including CE, LC and MS in the Biopharmaceutical Industry (AT Europe 2015)
Analytical Technologies Europe: Symposium on the Practical Applications including CE, LC and MS in the Biopharmaceutical Industry (AT Europe 2015) Symposium Co-Chairs: Cari Sänger - van de Griend, Kantisto
More informationSymposium Co-Chairs: Steffen Kiessig, F. Hoffmann La Roche Ltd. David Michels, Genentech, a Member of the Roche Group
CE in the Biotechnology & Pharmaceutical Industries: 19 th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides and Small Molecules (CE Pharm 2017) Symposium Co-Chairs: Steffen
More informationClinical Trials Insight. World Pharmaceutical Frontiers
ABOUT CLINICAL TRIALS INSIGHT The cost of bringing a new drug to market is staggering. Major pharmaceutical companies now invest between $4 billion and $12 billion in developing each new product. Containing
More informationGeneric Series: Optimizing Brand Lifecycle Management
A Datamonitor report Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition Published: Jun-08 Product Code: Providing you
More informationPrincipal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
More informationINDUSTRY PERSPECTIVE ON THE CONTROL OF VISIBLE PARTICLES
INDUSTRY PERSPECTIVE ON THE CONTROL OF VISIBLE PARTICLES Tapan Das Biologics Development, Bristol-Myers Squibb European Biopharmaceutical Enterprises (EBE) satellite Session CMC Strategy Forum Europe 2017,
More informationGlobal Biologics Regulatory Trends Challenges and Opportunities..
Global Biologics Regulatory Trends Challenges and Opportunities.. Wassim Nashabeh VP, Regulatory Policy and International Operations F.Hoffmann La-Roche, Basel, Switzerland picture placeholder Page 2 N-linked
More informationM&A Focus: Biotechnology
WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,
More informationAnalytical Technologies Europe: Symposium on the Practical Applications including CE, LC and MS in the Biopharmaceutical Industry (AT Europe 2018)
Analytical Technologies Europe: Symposium on the Practical Applications including CE, LC and MS in the Biopharmaceutical Industry (AT Europe 2018) Symposium Co-chairs: Christof Finkler, F. Hoffmann - La
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationModern Approaches to Process Understanding
Biomanufacturing and Process Development (BPD) Modern Approaches to Process Understanding Thursday, September 18, 2014 1:00 pm - Registration begins 1:15 5:00 pm - Presentations & Networking North Carolina
More informationRegulatory Sciences for Biologics and Vaccines: Accelerating Development and Enabling Manufacturing Innovation
Program Regulatory Sciences for Biologics and Vaccines: Accelerating Development and Enabling Manufacturing Innovation April 23-26, 2017 Lansdowne Resort Leesburg, VA, USA Conference Co-Chairs Prof. Antonio
More informationDISSOLUTION AND TRANSLATIONAL MODELING STRATEGIES ENABLING PATIENT-CENTRIC PRODUCT DEVELOPMENT
THE UNIVERSITY OF MARYLAND CENTER FOR EXCELLENCE IN REGULATORY SCIENCE AND INNOVATION AND THE FOOD AND DRUG ADMINISTRATION PRESENT: DISSOLUTION AND TRANSLATIONAL MODELING STRATEGIES ENABLING PATIENT-CENTRIC
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationEnabling Precision Medicine: The Role of Genetics in Clinical Drug Development A Workshop
A Collaboration between the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health Enabling Precision Medicine: The Role of Genetics in Clinical Drug
More informationPatients are Counting on Us: It s Time to Act
Patients are Counting on Us: It s Time to Act Brian Johnson Chairman Rx-360 Senior Director Supply Chain Security Pfizer, Inc. 24 th Global GS1 Healthcare Conference October 2, 2013 THE WALL STREET JOURNAL
More informationWednesday, June 13. 7:00 a.m. 5:30 p.m. Registration Open 7:00 a.m. 8:30 a.m. Continental Breakfast
Wednesday, June 13 7:00 a.m. 5:30 p.m. Registration Open 7:00 a.m. 8:30 a.m. Continental Breakfast 2018 PDA Container Closure Performance and Integrity Conference Assuring Packaging Quality in Delivery
More informationIntroductions and Perspectives on International Harmonization
Introductions and Perspectives on International Harmonization FDA/PQRI Conference on Evolving Product Quality September 17 th 2014 Mark Rosolowsky, PhD Vice President Global Regulatory Sciences CMC Bristol-Myers
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationQbD Concepts Applied to Qualification and Transfer of Analytical Methods
QbD Concepts Applied to Qualification and Transfer of Analytical Methods CMC Strategy Forum Latin America - 2014 Patrick Swann Senior Director Technical Development QbD = Quality by Design QbD - A systematic
More informationBiotechnology business models work: Evidence from the pharmaceutical marketplace J. Leslie Glick Date Received (in revised form): 5th December, 2007
Biotechnology business models work: Evidence from the pharmaceutical marketplace J. Leslie Glick Date Received (in revised form): 5th December, 2007 J. Leslie Glick is an independent advisor to corporate
More informationDivision of Docket Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
Connecting People, Science and Regulation Bethesda Towers 4350 East West Highway Suite 600 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org PDA Europe ggmbh Am Borsigturm
More informationTECHNICAL AND REGULATORY ASPECTS OF PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT: ICH Q12
TECHNICAL AND REGULATORY ASPECTS OF PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT: ICH Q12 MOHEB NASR PHRMA ICH Q12 TOPIC LEAD WCBP 2018 JANUARY 31, 2018 WASHINGTON, D.C. DISCLAIMERS The speaker is solely
More informationWelcome to Bioassays 2015: Scientific Approaches & Regulatory Strategies
Welcome to Bioassays 2015: Scientific Approaches & Regulatory Strategies On behalf of the Scientific Organizing Committee and CASSS, we are excited to welcome you to Bioassays 2015: Scientific Approaches
More informationGLOBAL COALITION FOR GOOD WATER GOVERNANCE
GLOBAL COALITION FOR GOOD WATER GOVERNANCE Launched at the 2016 World Water Week in Stockholm, Sweden The OECD Principles on Water Governance On 4 June 2015, the OECD Principles on Water Governance were
More informationStrategies for building a global healthcare biotechnology company
James A. Geraghty is Senior Vice-President of International Development and is an officer of Genzyme Corporation. In 1993 Genzyme Transgenics was founded and Mr Geraghty served as President and CEO until
More informationIndustry Perspectives on Visible Particle Requirements and Practices An overview of EBE position paper. S. Mathonet on behalf of EBE
Industry Perspectives on Visible Particle Requirements and Practices An overview of EBE position paper S. Mathonet on behalf of EBE CASSS CMC Strategy Forum EBE satellite session Sorrento May 5, 2014 2
More informationPharmaceuticals and Product Stewardship. Sierra Fletcher Product Stewardship Institute April 29, 2011
Pharmaceuticals and Product Stewardship Sierra Fletcher Product Stewardship Institute Who is the Product Stewardship Institute? Non profit founded in 2000 Membership 47 States 200+ Local governments 70+
More informationTechnical Report No. 60 Process Validation: A Lifecycle Approach
Technical Report No. 60 Process Validation: A Lifecycle Approach Paradigm Change in Manufacturing Operations SM PDA Task Force on Technical Report No. 60: Process Validation: A Lifecycle Approach Authors
More informationCMC Forum Europe, 2013
Lessons Learned from Two Case Studies in the FDA QbD Biotech Pilot CMC Forum Europe, 2013 Lynne Krummen, Ph.D. Global Head Roche Technical Regulatory, Biologics Global Lead, Roche QbD Core Team Case Study
More informationUS FDA and International Regulatory Efforts in Cellular and Gene Therapies
US FDA and International Regulatory Efforts in Cellular and Gene Therapies ISCT Satellite Global Regulatory Perspectives Workshop January 27, 2013 Kimberly Benton, Ph.D. Deputy Director, Division of Cellular
More informationTravel Flash Report. Winter 2018
Travel Flash Report Winter 2018 Summary Key Takeaways Mobile Trends in Travel Cross-device and Last-minute Behavior Focus on Apps Seasonality Appendix 2 Key Takeaways Criteo s deep dive into travel data
More informationAdvanced Concepts for Change Control of Analytical Procedures with ICH Q12 Coming
Advanced Concepts for Change Control of Analytical Procedures with ICH Q12 Coming Dr. Jörg Hoffmann / Global Drug Product Governance and CMC Compliance, Merck KGaA (EMD Serono in US) IFPAC Annual Meeting,
More informationThe Unfinished Story of Quality-by-Design (QbD)
The Unfinished Story of Quality-by-Design (QbD) In the Pharmaceutical Industry Bert T. Frohlich, Ph.D. Principal & Owner Biopharm Designs Presentation to ISPE Chapter Meeting 10 November 2016 Outline The
More information2018 Pre-Filled Syringes Forum:
2018 Pre-Filled Syringes Forum: Strategic Development, Safety & Regulatory Compliance, and Commercialization of Pre-Filled Syringes April 3 4, 2018, Racquet Club of Philadelphia, PA Featuring Lessons Learned
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationThe Changing Pharma Commercial Model in 2010 and Beyond Delivering the Customer Experiences Physicians Want Author: John Mack
www.pharmamarketingnews.com May 2010 Vol. 9, No. 5 Published by VirSci Corp. www.virsci.com Webinar Highlight/Service Review The Changing Pharma Commercial Model in 2010 and Beyond Delivering the Customer
More informationOctober 23+24, Dr. Axel Herberg, CEO
Gerresheimer: Excellent prospects as a unique supplier to the Pharma & Life Science Industry Gerresheimer Capital Markets Day October 23+24, 2008 Dr. Axel Herberg, CEO 0 Disclaimer This presentation may
More informationA French Biotechnology company dedicated to the development and production of human endocrine cell lines. Innovation In Healthcare April 2012
A French Biotechnology company dedicated to the development and production of human endocrine cell lines Innovation In Healthcare 16-17 April 2012 1 French Biotechnology company Founded in S2 2004 in Paris
More informationMeeting Report. Pharma Success in Product Development Does Biotechnology Change the Paradigm in Product Development and Attrition
The AAPS Journal, Vol. 18, No. 1, January 2016 ( # 2015) DOI: 10.1208/s12248-015-9833-6 Meeting Report Pharma Success in Product Development Does Biotechnology Change the Paradigm in Product Development
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationInternational Association for Biologicals
International Association for Biologicals Presentation to Japanese Biologicals Forum by Tony Lubiniecki Tokyo, 16January2008 Scientific Society established in 1955 Headquartered in Switzerland Recognized
More informationSHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17
SHORT COURSE SUNDAY, SEPTEMBER 17 OMNI PROVIDENCE HOTEL PROVIDENCE, RI Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SPONSORED BY: Organized by: www.bostonsociety.org
More informationINO Therapeutics is now
INO Therapeutics is now The materials contained herein are a description of our business. They do not purport to be all inclusive or contain all information that you desire. This document includes or may
More informationCaSSS CMC Strategy Forum A Practical Approach to the Analysis and Immunogenic Potential of Aggregates and Particles
CaSSS CMC Strategy Forum A Practical Approach to the Analysis and Immunogenic Potential of Aggregates and Particles January 9, 2011 Renaissance Mayflower Hotel Washington, D.C. Visual Inspection of Parenterals
More informationThird Annual Risk Management and Drug Safety Summit
Two powerhouse panels added for 2010 An exclusive summit presented by FDAnews in conjunction with United BioSource and the Center for Medicine in the Public Interest REMS Veterans Share Their Battlefront
More informationDeclaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance
Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance January 2016 Antimicrobials, and specifically antibiotics, play a crucial role in modern
More informationInvestigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations
More informationThe European Medical Technology Industry. in figures / 2018
The European Medical Technology Industry in figures / 2018 Table of contents What is Medical Technology? 4 Innovation 10 Employment 14 Companies 18 Expenditure on Medical Technology 20 MedTech Market in
More informationProtein Aggregation & Biological Consequences Focus Group
PABC Protein Aggregation & Biological Consequences Focus Group Goals 2013 & Activities summary 2012/2013 since last NBC Karoline Bechtold-Peters Vision & Mission The AAPS Protein Aggregation and Biological
More informationThe Global Partnership on Wealth Accounting and the Valuation of Ecosystem Services
WAVES Capabilities Brochure April 2017 The Global Partnership on Wealth Accounting and the Valuation of Ecosystem Services Valuing Natural Capital for Sustainable Development www.wavespartnership.org WAVES
More informationCompound management outsourcing: how to build the trust?
Compound management outsourcing: how to build the trust? Olivier Casamitjana SVP, Global Compound Management Head Evotec AG SLAS conference, March 2017, Olivier Casamitjana Agenda Evotec Overview Outsourcing:
More informationGlobal and China Monoclonal Antibody Industry Report, Oct. 2014
Global and China Monoclonal Antibody Industry Report, 2014-2019 Oct. 2014 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis,
More informationTHE STATE OF DIGITAL EXCELLENCE IN THE PHARMACEUTICAL INDUSTRY, 2015: CAPABILITIES
April 2, 2015 THE STATE OF DIGITAL EXCELLENCE IN THE PHARMACEUTICAL INDUSTRY, 2015: CAPABILITIES Firms Require a More Disciplined Approach to Improving Digital Maturity by Tim van Tongeren and Dennis van
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationParticulate Matter and Visual Inspection: Industry Trends 2015
Particulate Matter and Visual Inspection: Industry Trends 2015 John G. Shabushnig, Ph.D. Insight Pharma Consulting, LLC November 2015 Agenda FDA Recalls and 483 Observations Industry Benchmarking Survey
More informationExplore Ways to Enhance Collaboration Between Key Players
Joint EFGCP / DIA / EMA Better Medicines for Children Conference 2014 on Explore Ways to Enhance Collaboration Between Key Players 30 th September & 1 st October 2014 EMA, London, United Kingdom Organised
More informationBiotherapeutic product characterization to support accelerated process development
Biotherapeutic product characterization to support accelerated process development Kyle Zingaro, Ph.D. Alexion Pharmaceuticals 2015 Biomanufacturing Technology Summit June 25, 2015 Our Mission: Treating
More informationAmgen Supply Chain Segmentation The Journey to October 23, 2014
Amgen Supply Chain Segmentation The Journey to 2022 October 23, 2014 Introduction Rayne Waller VP Global Supply Chain at Amgen Responsible for: Corporate and Regional Supply Chain Functions Contract Manufacturing
More informationThe Patient-Reported Outcome (PRO) Consortium:
The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the
More informationBasis for Setting Acceptance Criteria. Basis for setting acceptance criteria
Basis for Setting Acceptance Criteria Representing EBE Brian Withers, Director CMC Regulatory Affairs, Abbott laboratories Basis for setting acceptance criteria Industry considerations: How to allow for
More information